mTOR Signalling and Cancer Therapy

mTORC1 vs mTORC2: Different Inputs, Different Outputs

mTOR forms two structurally and functionally distinct complexes. mTORC1 — defined by its RAPTOR subunit — is the rapamycin-sensitive complex that integrates growth factor (AKT-mediated RHEB activation), amino acid (RAG GTPase-Ragulator lysosomal pathway), energy (AMPK opposition), and oxygen (REDD1-mediated TSC activation under hypoxia) signals. mTORC1 output drives protein synthesis (S6K1→ribosome biogenesis, 4EBP1→cap-dependent translation), lipid synthesis (SREBP1 activation), and autophagy suppression (ULK1 Ser757 phosphorylation).

mTORC2—defined by its RICTOR subunit—is relatively insensitive to acute rapamycin exposure, although prolonged effects vary by cell type. It phosphorylates AKT at Ser473 and regulates PKC and SGK-family signalling. Blocking both complexes changes feedback and target coverage, but broader biochemical inhibition does not automatically produce greater clinical efficacy or tolerability.

The Paradoxical AKT Activation Problem

A critical pharmacological limitation of mTORC1-selective inhibitors (rapamycin, everolimus, temsirolimus) is paradoxical AKT activation through IRS-1 feedback relief. mTORC1-activated S6K1 normally phosphorylates IRS-1 at inhibitory serine residues (Ser302, Ser636/639), reducing PI3K recruitment to the insulin/IGF-1 receptor. When mTORC1 is inhibited by rapamycin/everolimus, this negative feedback is released, allowing stronger PI3K → PDK1 → AKT Thr308 phosphorylation.

mTORC1 inhibition can therefore increase selected upstream or AKT phosphorylation readouts in some contexts. Dual PI3K/mTOR and mTOR-kinase inhibitors were designed partly to alter this feedback, but broader target coverage can also increase toxicity. The presence of feedback in a model is not proof that a dual inhibitor will improve clinical outcomes.

mTOR Inhibitors and Disease-Specific Evidence

Everolimus and temsirolimus have been studied and labelled in specific oncology and non-oncology settings, with regimen, prior-therapy and disease requirements that cannot be summarised safely by the target name alone. Landmark trials such as BOLERO-2 show how evidence was established in a defined population, while current prescribing information remains the source for present-day use.

Allosteric rapalogs incompletely suppress some mTORC1 outputs and generally do not acutely inhibit mTORC2. ATP-competitive mTOR-kinase and dual PI3K/mTOR compounds change target coverage and feedback, but development has also been constrained by toxicity and limited therapeutic windows. Mechanistic completeness is not the same as clinical superiority.

Key Takeaways

• ·mTORC1 (RAPTOR complex) integrates growth factor, amino acid, energy, and oxygen signals to drive cap-dependent translation (via 4EBP1 and S6K1), lipid synthesis, and autophagy suppression — making it the central anabolic hub in cancer.
• ·mTORC2 (RICTOR complex) phosphorylates AKT Ser473 for full activation and PKCα for cytoskeletal regulation, and is rapamycin-insensitive at acute timepoints — a key limitation of allosteric mTOR inhibitors.
• ·Relief of S6K–IRS feedback can increase upstream signalling in some settings, but it is one of several mechanisms that can limit rapalog activity.
• ·Everolimus and temsirolimus evidence is disease-, regimen- and label-specific; a pathway page should not substitute for current prescribing information.
• ·TSC1/TSC2 loss can increase RHEB–mTORC1 signalling, while clinical phenotype and treatment evidence still depend on the specific disease and context.